NEWTOWN, Pa., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) announced the pricing of an underwritten public offering of 2,121,212 shares of its Class A common stock at a public offering price of $8.25 per share, before underwriting discounts and commissions. The net proceeds to Helius from this offering, after deducting the underwriting discounts, commissions and estimated offering expenses payable by Helius, are expected to be approximately $15.7 million. The offering is expected to close on or about Monday, November 19, 2018, subject to customary closing conditions including the approval of the Toronto Stock Exchange.
BTIG, LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering. Haywood Securities Inc. is acting as a co-manager for the offering. Helius has granted the underwriters a 30-day option to purchase up to an additional 318,182 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNSTM).
